Jump to Home page | Jump to about us page | Jump to products | Jump to search page | Jump to FAQ | Jump to contact us | Jump to development | Jump to investors | Jump to careers | Jump to accessibility

Pipeline

ProStrakan's primary strength is in its multidisciplinary staff of about 30 professionals in R&D, trained throughout Europe and the United States, whose expertise covers all aspects of research and development. The development function is based at Galashiels in Scotland.

 

ProStrakan's R&D management has a significant track record with a broad spread of expertise including R&D, product development and approvals in both big pharma and biotech environments.

Project
Phase 1
Phase 2
Phase 3
Reg
Launch
Indication
Rectogesic EU




Marketed
Anal fissure pain
Tostran EU




Marketed Male Hypogonadism
Droperidol EU




Marketed Post-operative nausea and vomiting
Abstral EU




Marketed Breakthrough cancer pain
Sancuso EU



In Reg.
2010
Anti-emetic, cancer supportive care
Sancuso USA




Marketed Anti-emetic, cancer supportive care
Abstral USA



In Reg.

2010

Breakthrough cancer pain
Cellegesic USA




2010
Anal fissure pain
FORTESTA USA



In Reg. 2010
Male Hypogonadism
Testosterone-glucoside (oral pro-drug)




TBC
Male Hypogonadism